Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
Completed
National Cancer Institute (NCI)
Phase 1
2002-06-01
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of atrasentan in treating patients who have
progressive or recurrent malignant glioma.
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
Completed
Abbott
Phase 2
2002-05-01
The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study
is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as
measured by rate of rise in the PSA (primary objective).
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Completed
National Cancer Institute (NCI)
Phase 2
2003-05-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: This phase II trial is studying how well atrasentan works in treating patients with
locally recurrent or metastatic kidney cancer.
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Completed
Eastern Cooperative Oncology Group
Phase 2
2003-05-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: This phase II trial is studying how well atrasentan works in treating patients with
locally recurrent or metastatic kidney cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
